Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Goldman Sachs cancelled a four-year-old policy to only take public companies that had two diverse board members, a ...

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.

Goldman Sachs will drop a demand that corporate boards of directors include women and members of minority groups as financial ...

Goldman Sachs Group Inc. is killing a significant pledge it made to refuse initial public offering business with companies ...